VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Immune escape is a prerequisite for tumor development. To avoid the immune system, tumors develop different mechanisms, including T cell exhaustion, which is characterized by expression of immune inhibitory receptors, such as PD-1, CTLA-4, Tim-3, and a progressive loss of function. The recent development of therapies targeting PD-1 and CTLA-4 have raised great interest since they induced long-lasting objective responses in patients suffering from advanced metastatic tumors. However, the regulation of PD-1 expression, and thereby of exhaustion, is unclear. VEGF-A, a proangiogenic molecule produced by the tumors, plays a key role in the development of an immunosuppressive microenvironment. We report in the present work that VEGF-A produced in the tumor microenvironment enhances expression of PD-1 and other inhibitory checkpoints involved in CD8+ T cell exhaustion, which could be reverted by anti-angiogenic agents targeting VEGF-A–VEGFR. In view of these results, association of anti-angiogenic molecules with immunomodulators of inhibitory checkpoints may be of particular interest in VEGF-A-producing tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Preclinical studies have demonstrated that VEGF blockade can reverse T cell failure and enhance the therapeutic effect of ICI [59,60].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [59]
In the citing paper
“expression of co-inhibitory receptors, including PD-1 by CD8 + CTLs”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Voron et al., 2015
In the citing paper
“First, increased VEGF directly inhibits CTL trafficking, proliferation, and effector function22”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [22]
In the citing paper
“Secondly, VEGF could inhibit the maturation of DC, induce the exhaustion of T cells, promote the proliferation of Tregs, and increase the ratio of MDSCs [90–93].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 1×
“2015 Vol. 212 No. 2 139–148 www.jem.org/cgi/doi/10.1084/jem.20140559 139 Brief Definit ive Report One of the major processes involved in tumor appearance and growth is the capacity of tumor cells to develop escape mechanisms to the immune system (Schreiber et al., 2011).”
BackgroundInfluentialWherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 1×
“The mechanisms involved in PD-1 expression and exhaustion of tumor-infiltrating T cells are poorly understood, even though a link to antigen persistence has been suggested (Wherry, 2011).”
BackgroundSafety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103 · cited 1×
“In tumors or during chronic viral infections, PD-1 expression is maintained (Wherry et al., 2007).”
BackgroundTargeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072 · cited 6×
“Cell surface-staining was performed on tumor-infiltrating cells using antiCD8 (53–6.7; eBioscience), anti–PD-1 (J43; eBioscience), anti–CTLA-4 (UC10-4B9; BioLegend), anti–Lag-3 (C9B7W; BioLegend), anti–Tim-3 (RMT3-23; BioLegend), anti–mouse VEGF-R2 (89B3A5; BioLegend), and anti–mouse VEGF-R1 (141522; R&D Systems).”
BackgroundInfluentialBlackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062 · cited 1×
“To determine whether VEGF-R1 or VEGF-R2 are involved in the T cells express these receptors the more they are dysfunctional (Blackburn et al., 2009).”
BackgroundGabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
Cited by
Items 201–300 of 1,000
Federico, A. D., Rizzo, A., Carloni, R., Giglio, A. D., Bruno, R., Ricci, D., & Brandi, G. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2009455 · Cited by 105
“mice was observed, suggesting that tumor-derived VEGF may limit the activity of PD-1 inhibitors [39].”
BackgroundBidirectional Crosstalk Between Cancer Stem Cells and Immune Cell Subsets
Müller, L., Tunger, A., Plesca, I., Wehner, R., Temme, A., Westphal, D., Meier, F. E., Bachmann, M. P., & Schmitz, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00140 · Cited by 103
Kim, H., Shim, B. Y., Lee, S., Lee, J. Y., Lee, H. J., & Kim, I.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189795 · Cited by 117
“Additionally, anti-angiogenic agents downregulate the inhibitory checkpoint on CD8+ T cells and reverse T-cell exhaustion in the TME [93].”
BackgroundTherapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies
Comunanza, V., & Bussolino, F. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00101 · Cited by 110
“, 2016) indicating a mechanism of therapeutic resistance and a potential target to therapy (Ott et al., 2015; Voron et al., 2015).”
BackgroundInfluentialBo, M. D., Mattia, E. D., Baboçi, L., Mezzalira, S., Cecchin, E., Assaraf, Y. G., & Toffoli, G. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100702 · Cited by 101
Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma
Hirsch, L., Flippot, R., Escudier, B. J., & Albiges, L. K. (2020) · Drugs · doi:10.1007/s40265-020-01327-7 · Cited by 102
“Antiangiogenic agents targeting VEGF-A also revert the expression of inhibitory checkpoints on CD8 T cells in the mouse model [28].”
BackgroundMissiaen, R., Mazzone, M., & Bergers, G. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.06.002 · Cited by 94
“CTLA-4, Lag-3, TIM-3) on T cells contributing to T-cell anergy and exhaustion [46].”
BackgroundBao, X., Zhang, H., Wu, W., Cheng, S., Dai, X., Zhu, X., Fu, Q., Tong, Z., Liu, L., Zheng, Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001437 · Cited by 94
Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs
Montemagno, C., & Pagès, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00584 · Cited by 104
“Moreover, inhibition of VEGFA or VEGFR decreased the expression of immune checkpoints involved in immune tolerance, by T cells (Voron et al., 2015).”
BackgroundMechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance
Yang, M., Cui, M., Sun, Y., Liu, S., & Jiang, W. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01711-w · Cited by 109
Mangraviti, A., Raghavan, T., Volpin, F., Skuli, N., Gullotti, D., Zhou, J., Asnaghi, L., Sankey, E., Liu, A., Wang, Y., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14990-w · Cited by 93
Walsh, R. J., & Soo, R. A. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920937902 · Cited by 100
Pelekanou, V., Barlow, W. E., Nahleh, Z. A., Wasserman, B., Lo, Y.-C., von Wahlde, M.-K., Hayes, D., Hortobagyi, G. N., Gralow, J., Tripathy, D., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1005 · Cited by 91
“VEGF in the tumor microenvironment enhances expression of PD-1 and other inhibitory checkpoints involved in T-cell exhaustion, and this effect can be reverted by antiangiogenic agents such as bevacizumab (21).”
BackgroundInfluentialQian, C., Liu, C., Liu, W., Zhou, R., & Zhao, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1291530 · Cited by 101
“VEGFA acts on VEGFR2 and increases the expression levels of TIM-3, CTLA-4, and Lag-3 on CD8 + T cells in a dose-dependent manner, and the expression levels of these molecules correlates with the level of T-cell exhaustion (54).”
BackgroundLeong, A., & Kim, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228689 · Cited by 101
Drew, Y., Kim, J., Penson, R. T., O’Malley, D. M., Parkinson, C., Roxburgh, P., Plummer, R., Im, S., Imbimbo, M., Ferguson, M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2249 · Cited by 103
The Resistance Mechanisms of Lung Cancer Immunotherapy
Wang, F., Wang, S., & Zhou, Q. H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.568059 · Cited by 98
“Multiple mechanisms are involved in the interaction of VEGF with antitumor immunity: (1) VEGF prevented the commitment of lymphoid progenitors, decreasing progression to the T-cell lineage (212); (2) VEGF signaling promotes the infiltration of Tregs through a selective endothelium and reduces trafficking and extravasa…”
BackgroundTrials and tribulations of pancreatic cancer immunotherapy
Principe, D. R., Korc, M., Kamath, S. D., Munshi, H. G., & Rana, A. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.01.031 · Cited by 100
“VEGF has similarly been shown to modulate immune checkpoint expression on CD8+ T-cells, thereby contributing to a state of functional exhaustion [168].”
BackgroundHypoxia Supports Differentiation of Terminally Exhausted CD8 T Cells
Bannoud, N., Dalotto‐Moreno, T., Kindgard, L., García, P. A., Blidner, A. G., Mariño, K. V., Rabinovich, G. A., & Croci, D. O. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.660944 · Cited by 98
“In this sense, Voron and colleagues demonstrated that VEGF-A increases the percentages of TIM-3expressing CD8 T cells and highlighted the role of VEGF-A in resistance to anti-PD-1 treatment in a murine model of colorectal cancer (26).”
BackgroundInfluentialImmunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies
Zhou, S., & Yang, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1129465 · Cited by 122
“The anti-VEGFR drug Lenvatinib was found to perform immunoregulation by reducing TAMs infiltration and increasing the activity of CD8 T cells (155, 156).”
BackgroundImmune recognition of irradiated cancer cells
Wennerberg, E., Vanpouille‐Box, C., Bornstein, S., Yamazaki, T., Demaria, S., & Galluzzi, L. (2017) · Immunological Reviews · doi:10.1111/imr.12568 · Cited by 92
Albonici, L., Giganti, M. G., Modesti, A., Manzari, V., & Bei, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20122970 · Cited by 93
Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma
Kammerer‐Jacquet, S., Deleuze, A., Saout, J., Mathiéu, R., Laguerre, B., Verhoest, G., Dugay, F., Belaud‐Rotureau, M., Bensalah, K., & Rioux-Leclercq, N. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071692 · Cited by 91
Chamseddine, A. N., Assi, T., Mir, O., & Chouaïb, S. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107986 · Cited by 94
Li, S., Li, K., Wang, K., Yu, H., Wang, X., Shi, M., Liang, Z., Zhou, Y., Hu, Y., Li, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43462-1 · Cited by 98
“VEGF-A increases PD-1 expression on CD8 + T cells and the coexpression of other immune checkpoints, such as CTLA-4, Tim-3, andLag-3 60 .”
Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies
Ou, X., Gao, G., Habaz, I. A., & Wang, Y. (2024) · MedComm · doi:10.1002/mco2.694 · Cited by 115
Regulatory Mechanisms of Inhibitory Immune Checkpoint Receptors Expression
Curdy, N., Lanvin, O., Laurent, C., Fournié, J.-J., & Franchini, D.-M. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.07.002 · Cited by 83
Current perspectives on the tumor microenvironment in hepatocellular carcinoma
Santhakumar, C., Gane, E. J., Liu, K., & McCaughan, G. W. (2020) · Hepatology International · doi:10.1007/s12072-020-10104-3 · Cited by 90
“Furthermore, VEGF recruits myeloid-derived suppressor cells (MDSCs) and regulatory T cells, inhibits T cell function and dendritic cell maturation and enhances inhibitory checkpoint expression on CD8+ T cells, thereby contributing to the immunosuppressive milieu of the TME [18, 19].”
BackgroundNakajima, T. E., Kadowaki, S., Minashi, K., Nishina, T., Yamanaka, T., Hayashi, Y., Izawa, N., Muro, K., Hironaka, S., Kajiwara, T., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3559 · Cited by 82
Choueiri, T. K., Albiges, L. K., Barthélémy, P., Iacovelli, R., Emambux, S., Molina‐Cerrillo, J., Garmezy, B., Barata, P. C., Basu, A., Bourlon, M. T., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01758-6 · Cited by 96
Tumor cell-intrinsic Tim-3 promotes liver cancer via NF-κB/IL-6/STAT3 axis
Zhang, H., Song, Y., Yang, H., Liu, Z., Gao, L., Liang, X., & Ma, C. (2018) · Oncogene · doi:10.1038/s41388-018-0140-4 · Cited by 90
Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response
Xiao, Q., Nobre, A., Piñeiro, P., Berciano‐Guerrero, M., Alba, E., Cobo, M., Lauschke, V. M., & Barragán, I. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010286 · Cited by 83
“For example, VEGFA can upregulate PD-1 expression on CD8+ T cells, while TGF-β enhances PD-L1 expression on tumor cells [31,32].”
BackgroundEsteban-Fabró, R., Willoughby, C. E., Piqué‐Gili, M., Montironi, C., Abril‐Fornaguera, J., Peix, J., Torrens, L., Mesropian, A., Balaseviciute, U., Miró‐Mur, F., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2517 · Cited by 91
Molecular Network Basis of Invasive Pituitary Adenoma: A Review
Yang, Q., & Li, X. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00007 · Cited by 81
“The immune escape modulated by VEGF was reported (24) and left untested in pituitary adenomas.”
BackgroundZhang, X., Wang, J., Shi, J., Jia, X., Dang, S., & Wang, W. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.4846 · Cited by 86
Hatanaka, T., Kakizaki, S., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., et al. (2022) · Hepatology International · doi:10.1007/s12072-022-10358-z · Cited by 90
Navigating tumor angiogenesis: therapeutic perspectives and myeloid cell regulation mechanism
Yang, F., Lee, G., & Fan, Y. (2024) · Angiogenesis · doi:10.1007/s10456-024-09913-z · Cited by 94
“Inhibiting VEGF expression from these T cells further suggests their role in promoting abnormal tumor vessel phenotypes [63].”
BackgroundSato, M., Tamura, R., Tamura, H., Mase, T., Kosugi, K., Morimoto, Y., Yoshida, K., & Toda, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050695 · Cited by 88
“Interestingly, PD-1/PD-L1 expressions are known to be associated with VEGF-A exposure [45,46].”
Backgroundγδ T Cells Promote Steatohepatitis by Orchestrating Innate and Adaptive Immune Programming
Torres‐Hernandez, A., Wang, W., Nikiforov, Y., Tejada, K., Torres, L., Kalabin, A., Adam, S., Wu, J., Lu, L., Chen, R., et al. (2020) · Hepatology · doi:10.1002/hep.30952 · Cited by 80
de Aguiar, R. B., & de Moraes, J. Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01023 · Cited by 88
“Similarly, the expression levels of VEGF were found associated with decreased activation of CD8 T and TH1 cell response on colorectal tumors (13), and the VEGF-enhanced expression of inhibitory checkpoints on CD8 T cells can be reverted by VEGF- and VEGFR-targeted agents (14).”
BackgroundNon-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells
Yong, S., Chung, J. Y., Song, Y., Kim, J., Ra, S., & Kim, Y. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119401 · Cited by 84
Li, S., Chen, J. Y., & Sun, Z. (2021) · 癌症:英文版 · doi:10.1002/cac2.12183 · Cited by 87
“Funding information NationalKeyResearch andDevelopmentProgram,Grant/AwardNumber: 2017YFSF090107;NationalNatural Science FoundationofChina,Grant/AwardNumbers: 82072996, 81874131;Hubei Province Natural ScienceFunds forDistinguished Abbreviations: PD-1, programmed cell death protein 1; PD-L1, programmed death ligand 1; N…”
BackgroundResultInfluentialDuffy, D., Rouilly, V., Braudeau, C., Corbière, V., Djebali, R., Ungeheuer, M., Josien, R., LaBrie, S. T., Lantz, O. J., Louis, D., et al. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.09.019 · Cited by 90
Manipulation of immune‒vascular crosstalk: new strategies towards cancer treatment
Zhao, Y., Yu, X., & Li, J. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.09.014 · Cited by 84
The LEAP Program: Lenvatinib Plus Pembrolizumab for the Treatment of Advanced Solid Tumors
Taylor, M. H., Schmidt, E. V., Dutcus, C. E., Pinheiro, E. M., Funahashi, Y., Lubiniecki, G. M., & Rasco, D. W. (2020) · Future Oncology · doi:10.2217/fon-2020-0937 · Cited by 82
Immunosuppressive effects of vascular endothelial growth factor (Review)
Ribatti, D. (2022) · Oncology Letters · doi:10.3892/ol.2022.13489 · Cited by 101
“In this context, VEGFA promotes the expression of check point molecules, including PD‐1, cytotoxic T lymphocyte‐associated antigen 4 (CTLA‐4), T‐cell immunoglobulin mucin receptor 3 and lymphocyte activation gene 3 protein (18).”
BackgroundChen, X., Feng, L., Huang, Y., Wu, Y., & Xie, N. (2022) · Cancers · doi:10.3390/cancers15010104 · Cited by 94
“In the tumor immune microenvironment, VEGF-A can upregulate the expression of PD-1 and other immune checkpoints in CD8+ T cells, resulting in PD-1 inhibitor resistance [210].”
BackgroundLeveraging the immune system to treat advanced thyroid cancers
French, J. D., Bible, K. C., Spitzweg, C., Haugen, B. R., & Ryder, M. M. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30277-7 · Cited by 81
Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma
Dai, X., Guo, Y., Hu, Y., Bao, X., Zhu, X., Fu, Q., Zhang, H., Tong, Z., Liu, L., Zheng, Y., et al. (2021) · Theranostics · doi:10.7150/thno.54648 · Cited by 88
Wang, P., Fang, X., Yin, T., Tian, H., Yu, J., & Teng, F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.628124 · Cited by 80
“This was confirmed in a pre-clinical study, which suggested that the application of antiVEGF-A antibody (sunitinib) in CT26 tumor-bearing mice increases the infiltration of cytotoxic tumor-infiltrating lymphocytes (TIL) and decreases PD-1 expression in CD8T cells (32).”
BackgroundLong Non-coding RNAs: Emerging Roles in the Immunosuppressive Tumor Microenvironment
Luo, Y., Yang, J., Yu, J., Liu, X., Yu, C., Hu, J., Shi, H., & Ma, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00048 · Cited by 81
Khouzam, R. A., Zaarour, R. F., Brodaczewska, K. K., Azakir, B., Venkatesh, G. H., Thiery, J., Terry, S., & Chouaïb, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.828875 · Cited by 83
Mitochondrial immune regulation and anti-tumor immunotherapy strategies targeting mitochondria
Bai, R., & Cui, J. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216223 · Cited by 89
Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab
Tamura, R., Tanaka, T., Ohara, K., Miyake, K., Morimoto, Y., Yamamoto, Y., Kanai, R., Akasaki, Y., Murayama, Y., Tamiya, T., et al. (2019) · Cancer Science · doi:10.1111/cas.13889 · Cited by 75
Dual role of endothelial Myct1 in tumor angiogenesis and tumor immunity
Kabir, A. U., Subramanian, M., Lee, D. H., Wang, X., Krchma, K., Wu, J., Naismith, T., Halabi, C. M., Kim, J. Y., Pulous, F. E., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb6731 · Cited by 84
Combination of Fruquintinib and Anti–PD-1 for the Treatment of Colorectal Cancer
Wang, Y., Wei, B., Gao, J., Cai, X., Xu, L., Zhong, H., Wang, B., Sun, Y., Guo, W., Xu, Q., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000463 · Cited by 75
“Abnormal tumor vasculature fosters an immunosuppressive TME that enables tumors to evade host immunosurveillance (29, 30).”
BackgroundYan, F., Pang, J., Peng, Y., Molina, J. R., Yang, P., & Liu, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162925 · Cited by 78
Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment
Chen, W., Shen, L., Jiang, J., Zhang, L., Zhang, Z., Pan, J., Ni, C., & Chen, Z. (2021) · Biomarker Research · doi:10.1186/s40364-021-00312-w · Cited by 79
“The immunosuppressive state is further relieved using immune checkpoint inhibitors (anti-PD-1/PD-L1 monoclonal antibodies, mAbs).”
BackgroundInfluentialPD-1+ and Foxp3+ T cell reduction correlates with survival of HCC patients after sorafenib therapy
Kalathil, S. G., Lugade, A. A., Miller, A., Iyer, R. V., & Thanavala, Y. M. (2016) · JCI Insight · doi:10.1172/jci.insight.86182 · Cited by 76
“Recently, the role of VEGF in increasing PD-1 expression on tumor antigen–specific T cells and downregulation of PD-1 expression by blockade of the VEGFA/VEGFR axis has been demonstrated in an experimental tumor model of colon cancer (16).”
BackgroundSchmitz-Winnenthal, F. H., Hohmann, N., Schmidt, T., Podola, L., Friedrich, T., Lubenau, H., Springer, M., Wieckowski, S., Breiner, K. M., Mikus, G., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1303584 · Cited by 80
“VEGFR2 is highly expressed on tumor vasculature as well as on certain tumor(32) and immune cells.(33,34) Moreover, the modulation of tumor growth with anti-VEGF-A and VEGFR2 antibodies and smallmolecule VEGFR2 inhibitors in cancer patients has established VEGFR2 as a therapeutic target in several cancer indications in…”
BackgroundMilestones in tumor vascularization and its therapeutic targeting
Palma, M. D., & Hanahan, D. (2024) · Nature Cancer · doi:10.1038/s43018-024-00780-7 · Cited by 87
Tada, K., Kitano, S., Shoji, H., Nishimura, T., Shimada, Y., Nagashima, K., Aoki, K., Hiraoka, N., Honma, Y., Iwasa, S., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0298 · Cited by 76
“VEGF-A augments MDSCs (28, 29) and inhibits DC maturation (30, 31), directly inhibits the activation and proliferation of T cells (32), and upregulates expression of the programmed death-1 molecule on T cells (33).”
BackgroundKalathil, S. G., Hutson, A. D., Barbi, J. J., Iyer, R. V., & Thanavala, Y. M. (2019) · JCI Insight · doi:10.1172/jci.insight.130116 · Cited by 86
Oncogenic Signal and Tumor Microenvironment in Hepatocellular Carcinoma
Nishida, N., & Kudo, M. (2017) · Oncology · doi:10.1159/000481246 · Cited by 77
Immune checkpoint blockade for the treatment of human hepatocellular carcinoma
Nishida, N., & Kudo, M. (2018) · Hepatology Research · doi:10.1111/hepr.13191 · Cited by 74
Angiocrine endothelium: from physiology to cancer
Pasquier, J., Ghiabi, P., Chouchane, L., Razzouk, K., Rafii, S., & Rafii, A. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02244-9 · Cited by 69
Reverting Immune Suppression to Enhance Cancer Immunotherapy
Guerrouahen, B. S., Maccalli, C., Cugno, C., Rutella, S., & Akporiaye, E. T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01554 · Cited by 77
“In ovarian cancer patients, VEGF enhances expression of PD-1 and other inhibitory checkpoints involved in CD8 T cell exhaustion (27).”
BackgroundThe unique immune microenvironment of liver metastases: Challenges and opportunities
Ciner, A., Jones, K. I., Muschel, R. J., & Brodt, P. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.003 · Cited by 79
Old Player-New Tricks: Non Angiogenic Effects of the VEGF/VEGFR Pathway in Cancer
Ntellas, P., Mavroeidis, L., Gκoura, S., Gazouli, I., Amylidi, A.-L., Papadaki, A., Zarkavelis, G., Mauri, D., Karpathiou, G., Kolettas, E., et al. (2020) · Cancers · doi:10.3390/cancers12113145 · Cited by 76
“VEGF-A also contributes to CD8+ T-cells exhaustion, in a VEGFR2 and NFAT (nuclear factor of activated T-cells) dependent manner, by promoting the expression of checkpoint molecules such as programmed cell death protein 1 (PD-1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), T-cell immunoglobulin mucin receptor…”
BackgroundInfluentialRecent advancements of antiangiogenic combination therapies in ovarian cancer
An, D., Banerjee, S. N., & Lee, J. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102224 · Cited by 70
Zhang, Y., Li, Y., Chen, K., Qian, L. M., & Wang, P. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01972-2 · Cited by 67
“As an example, VEGF has direct immunosuppressive effects by recruiting immunoinhibitory cells to suppress the activity of T cells and disrupting the maturation and antigen-presenting ability of DCs [17, 18].”
BackgroundInfluentialLu, S., Sun, X., Zhou, Z., Tang, H., Xiao, R., Lv, Q., Wang, B., Qu, J., Yu, J., Sun, F., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1235575 · Cited by 72
“…of colorectal cancer (CT26) targeting VEGFR therapy, it was found that targeting VEGF-a-VEGFR can reduce the co-expression of inhibitory receptors (PD-1, Tim-3, CTLA-4, and Lag-3) related to T cell failure and restore the CD8 + T cells in fi ltration into the tumor to produce IFN-g ability (114).”
BackgroundStrategies targeting angiogenesis in advanced non-small cell lung cancer
Wang, J., Chen, J., Guo, Y., Wang, B., & Chu, H. (2017) · Oncotarget · doi:10.18632/oncotarget.17957 · Cited by 68
“First, the pro-angiogenic factor VEGF-A is immunosuppressive and helps tumor cells evade immune surveillance by inhibiting T-cell infiltration and trafficking into the tumor and preventing the maturation of dendritic cells [95].”
BackgroundTargeted Anti-Mitochondrial Therapy: The Future of Oncology
Taghizadeh‐Hesary, F., Behnam, B., Akbari, H., & Bahadori, M. (2022) · Genes · doi:10.3390/genes13101728 · Cited by 64
“In a colon cancer mouse model, VEGF-A led to PD-1 expression on tumor-infiltrating CD8+ T cells [64].”
BackgroundImmune-resistant mechanisms in cancer immunotherapy
Kawakami, Y., Ohta, S., Sayem, M. A., Tsukamoto, N., & Yaguchi, T. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01611-x · Cited by 69
Lin, J., Tang, Y.-H., Zheng, H., Ye, K., Cai, J., Cai, L., Lin, W., Xie, J., Wang, J.-B., Lü, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44309-5 · Cited by 84
“Anti-angiogenesis therapy can reverse this immune suppressive nature and has the potential to improve the therapeutic response to immunotherapy 36 – 38 .”
Cancer Cells Exploit Notch Signaling to Redefine a Supportive Cytokine Milieu
Colombo, M., Mirandola, L., Chiriva‐Internati, M., Basile, A., Locati, M., Lesma, E. A., Chiaramonte, R., & Platonova, N. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01823 · Cited by 71
“Tumor-derived VEGF has been shown to enhance expression of PD-1 on activated CD8+ cells of colon carcinoma murine models through VEGFR2 signaling, which could be reverted by antiangiogenic agents targeting VEGF-A–VEGFR (251).”
BackgroundLamberti, G., Sisi, M., Andrini, E., Palladini, A., Giunchi, F., Lollini, P., Ardizzoni, A., & Gelsomino, F. (2020) · Cancers · doi:10.3390/cancers12113129 · Cited by 70
“The vascular endothelial growth factor (VEGF) is the most important proangiogenic factor, which also has pleiotropic effects on antitumor immune response since it inhibits antigen presentation, promotes regulatory T-cell infiltration and induces PD-L1 expression on tumor-infiltrated T-cells [116].”
BackgroundPD-1/PD-L1 expression in pancreatic cancer and its implication in novel therapies
Mucileanu, A., Chira, R. I., & Mircea, P. A. (2021) · Medicine and Pharmacy Reports · doi:10.15386/mpr-2116 · Cited by 61
“Therefore antiangiogenic agents could have an inhibitory effect on PD-1 expression [10].”
BackgroundFuture of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens
Song, M., Chen, X., Wang, L., & Zhang, Y. (2018) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2018.02.01 · Cited by 63
Uveal Melanoma, Angiogenesis and Immunotherapy, Is There Any Hope?
Castet, F., García‐Mulero, S., Pamplona, R. S., Cuellar, A., Casanovas, O., Mitjana, J. M. C., & Piulats, J. M. (2019) · Cancers · doi:10.3390/cancers11060834 · Cited by 70
“Moreover, VEGF (along with other angiogenic factors) plays a crucial role in modulating the immune system and fostering an immunosuppressive microenvironment: it directly suppresses dendritic cell maturation breast and colon carcinomas [39,186], inhibits T-cells by enhancing PD-1 and other inhibitory checkpoints in co…”
BackgroundFujiwara, Y., Mittra, A., Naqash, A. R., & Takebe, N. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.11 · Cited by 87
“However, VEGF not only has the ability to enhance angiogenesis but also has an immunosuppressive role by increasing Fas ligand expression in endothelial cells to reduce effector T cells and upregulate Tregs in the TME, contributing to ICI therapy resistance([175-177]).”
BackgroundPeters, S., Paz-Ares, L. G., Herbst, R. S., & Reck, M. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004863 · Cited by 65
Zhang, L., Feng, J., Kuang, T., Chai, D., Qiu, Z., Deng, W., Dong, K., Zhao, K., & Wang, W. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110019 · Cited by 73
Targeting tumor-infiltrating tregs for improved antitumor responses
Qin, D., Zhang, Y., Shu, P., Lei, Y., Li, X., & Wang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1325946 · Cited by 77
Advances and prospects of RNA delivery nanoplatforms for cancer therapy
Attia, M. S., Kijanka, G. S., Nguyen, N., Zhang, J., & An, H. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.09.009 · Cited by 66
“As well, ECM and the associated proteins exert other effects on TME through the regulatory rules in the escape mechanisms, including the expression of checkpoint molecules 386,387 .”
Franchini, D.-M., Lanvin, O., Tosolini, M., Patras de Campaigno, E., Cammas, A., Péricart, S., Scarlata, C.-M., Lebras, M., Rossi, C., Ligat, L., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.014 · Cited by 61
Holzgruber, J., Martins, C. P., Kulcsár, Z., Duplaine, A., Rasbach, E., Migayron, L., Singh, P. K., Statham, E., Landsberg, J., Boniface, K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51496-2 · Cited by 78
“In contrast, several other established regulators of T-cell-PD-1 9,12,13,26 , including multiple ILs and growth factors, did not modulate melanoma-PD-1 expression.”
Small molecules as theranostic agents in cancer immunology
Li, J., Valkenburgh, J. S. V., Hong, X., Conti, P. S., Zhang, X., & Chen, K. (2019) · Theranostics · doi:10.7150/thno.37218 · Cited by 65
“malignancies, can enhance the expression of PD-1 on CD8+ T cells through an overexpressed VEGF receptor causing the exhaustion of cytotoxic immune cells, which could be reversed by anti-angiogenic agents targeting VEGF-A–VEGFR [157].”
BackgroundVEGFR2 activity on myeloid cells mediates immune suppression in the tumor microenvironment
Zhang, Y., Huang, H., Coleman, M., Žiemys, A., Gopal, P., Kazmi, S. M. A., & Brekken, R. A. (2021) · JCI Insight · doi:10.1172/jci.insight.150735 · Cited by 66
“150735 VEGF in tumors was attributed to activation of the VEGFR2/PLCγ/calcineurin/NFAT pathway (18).”
BackgroundResultRecent advances of nanotechnology-based tumor vessel-targeting strategies
Zhu, D., Li, Y., Zhang, Z., Xue, Z., Hua, Z., Luo, X., Zhao, T., Lu, C. C., & Liu, Y. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01190-y · Cited by 61
“Fourth, VEGF blocks CTLs trafficking and mediates CTLs exhaustion and anergy by modulating the inhibitory immune checkpoints receptor on T cells, including PD-1, CTLA-4, and Tim-3 [25, 27].”
BackgroundNowak-Sliwinska, P. M., van Beijnum, J. R., Griffioen, C. J., Huinen, Z. R., Sopesens, N. G., Schulz, R., Jenkins, S. V., Dings, R. P. M., Groenendijk, F. H., Huijbers, E. J. M., et al. (2022) · Angiogenesis · doi:10.1007/s10456-022-09863-4 · Cited by 66
“Angiogenic factors, such as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF), are known to inhibit, directly or indirectly, T cell development and function [4, 5], promote T cell exhaustion through upregulation of immune checkpoints [6, 7], inhibit dendritic cell maturation [8], modulate ma…”
BackgroundEngineering chimeric antigen receptor T cells for solid tumour therapy
Liu, L., Qu, Y., Cheng, L., Yoon, C. W., He, P., Monther, A., Guo, T., Chittle, S. J., & Wang, Y. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1141 · Cited by 62
Park, H.-R., Shiva, A., Cummings, P., Kim, S., Kim, S., Lee, E., Leong, A., Chowdhury, S., Shawber, C. J., Carvajal, R. D., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-2838 · Cited by 66
Xu, J., Wang, Y., Chen, Y. L., Jia, R., Li, J., Gong, J. F., Li, J., Qi, C., Ye, H., Tan, C. R., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14942 · Cited by 62
“VEGF secreted by tumors can activate VEGFR signaling pathways in T cells; this leads to programmed cell death protein 1 (PD-1) receptor overexpression, which decreases T cell anti-tumor activity [6].”
BackgroundAlmawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 78
Vessel pruning or healing: endothelial metabolism as a novel target?
Cantelmo, A. R., Pircher, A., Kalucka, J. M., & Carmeliet, P. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1282465 · Cited by 64
Diedrichs‐Möhring, M., Kaufmann, U., & Wildner, G. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.02.003 · Cited by 62
“VEGF can induce regulatory T cells in tumors and also the expression of PD-1 on T cells, which causes their exhaustion (Konkel et al., 2010; Terme et al., 2013; Voron et al., 2015).”
BackgroundTargeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting
Aggen, D. H., Drake, C. G., & Rini, B. I. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3323 · Cited by 60
“In somemodel systems, VEGF TKIs also decrease immune cell PD1 expression (73).”
BackgroundFu, R., Li, Y., Jiang, N., Ren, B., Zang, C.-Z., Liu, L., Lv, W., Li, H., Weiss, S. J., Li, Z., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131507 · Cited by 64
Metadata
- Authors
- Voron, T., Colussi, O., Marcheteau, E., Pernot, S., Nizard, M., Pointet, A.-L., Latreche, S., Bergaya, S., Benhamouda, N., Tanchot, C., Stockmann, C., Combe, P., Berger, A., Zinzindohoue, F., Yagita, H., Tartour, E., Taieb, J., & Terme, M.
- Affiliations
- Inserm (FR)
- Hôpital Européen Georges-Pompidou (FR)
- Service d’immunologie biologique 2 , 3 , 4 , 5
- Department of Immunology, Juntendo University School of Medicine, Tokyo 113-8421, Japan 6
- INSERM U970, Paris Cardiovascular Research Center, Université Paris-Descartes, Sorbonne Paris Cité, 75015 Paris, France 1
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2015-01-19
- Volume
- 212
- Issue
- 2
- Pages
- 139-148
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC4322048
- OpenAlex
- W2156906256
- Cited by
- 1,179
- References
- 32
- Citations by year
- 2026: 81 · 2025: 100 · 2024: 121 · 2023: 142 · 2022: 169 · 2021: 147 · 2020: 127 · 2019: 92 · 2018: 81 · 2017: 51 · 2016: 50 · 2015: 16
- FWCI
- 28.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Ligue Contre le Cancer
- Assistance publique-Hôpitaux de Paris
- Fonds d’Etudes et de Recherche du Corps Médical
- Japan Society for the Promotion of Science (26290059)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- VEGF-A, PD-1, CTLA-4, TIM-3, CD8+ T cell exhaustion, tumor immune evasion, tumor microenvironment, anti-angiogenic therapy, VEGFR inhibition, immune checkpoint inhibitors, cancer immunotherapy
- MeSH terms
- Animals, Disease Models, Animal, Female, Neoplasms, Protein Binding, Signal Transduction, Gene Expression Regulation, Neoplastic, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Gene Expression Profiling, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor A, Mice, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.